PHARMACOSMOS A/S: Financial statements 2017
CVR: 15517085
Source: annual report 2017, Danish Business Authority
01/05/2016 – 30/04/2017
PHARMACOSMOS A/S (CVR 15517085) has filed annual accounts for 2017. In 2017, the company reported revenue of DKK 511,601,000 and a net result of DKK 158,715,000 compared with DKK 102,693,508 the year before. That is an increase of 14.2% compared with the year before. The profit margin was 31%. Equity in the 2017 report amounted to DKK 656,757,000. The solvency ratio was 67.9%. The company had 172 employees in the financial year.
- Revenue
- DKK 511,601,000
- Gross Profit
- DKK 314,843,000
- Profit/Loss
- DKK 158,715,000
- Equity
- DKK 656,757,000
- Total Assets
- DKK 966,772,000
- Employees
- 172
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 511.6 mio. | 314.8 mio. | 158.7 mio. | 656.8 mio. | 172 |
| 2016 | 448 mio. | 254.5 mio. | 102.7 mio. | 547.7 mio. | 111 |
| 2015 | - | 208.8 mio. | 81.1 mio. | 496.9 mio. | 105 |
| 2014 | - | 109.9 mio. | 6.2 mio. | 394.8 mio. | 105 |
| 2013 | - | 258 mio. | 115.5 mio. | 435.3 mio. | 106 |
Official annual report
Keep an eye on PHARMACOSMOS A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout PHARMACOSMOS A/S
PHARMACOSMOS A/S is a Danish company of the type Aktieselskab based in Holbæk, founded in 1991. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named PHARMACOSMOS PHARMACEUTICALS A/S and SOLOCHEM A/S. The management consists of Tobias Sidelmann Christensen, Claes Christian Strøm and Henrik Parker. The board consists of Jacob Tolstrup (chair), Lars Christensen, Lars Green and Martin Holst Lange. The company is owned by PHARMACOSMOS HOLDING A/S. The company has 327 employees (2026). In 2026, the company reported revenue of DKK 2,176,000,000 and a net result of DKK 714,000,000 compared with DKK 1,622,000,000 the year before. Equity in the 2026 report amounted to DKK 2,775,000,000.